Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 1, 2014, Pages 43-53

  Montoro García, Silvia ^a,b   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Antagonist; Collagen; Glycoprotein; Monoclonal antibody; Platelet; Thrombosis; Von Willebrand factor

Indexed keywords

ABCIXIMAB; AJW 200; ALX 0681; ANTITHROMBOCYTIC AGENT; ARC 15105; BLOOD CLOTTING FACTOR 8; CAPLACIZUMAB; CLOPIDOGREL; COLLAGEN; EGAPTIVON PEGOL; FIBRINOGEN RECEPTOR; GPG 290; HEPARIN; MEMBRANE PROTEIN; SZ 123; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE CORONARY SYNDROME; AMINO ACID SEQUENCE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BINDING SITE; BLEEDING TIME; BLOOD CLOTTING; BRAIN EMBOLISM; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CHADS2 SCORE; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN REFOLDING; REVIEW; SHEAR STRESS; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; VON WILLEBRAND DISEASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; PLATELET ACTIVATION; PROTEIN CONFORMATION; PROTEOLYSIS; VON WILLEBRAND FACTOR;

EID: 84890388131     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.840585     Document Type: Review

References (88)

1. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006;47:C7-12
2. Barter P, Kastelein J, Kastelein J. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003;168:195-211
3. da Costa Martins P, van den Berk N, Ulfman LH, et al. Platelet-monocyte complexes support monocytes adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler Thromb Vasc Biol 2004;24:193-9
4. Moroi M, Jung SM. A mechanism to safeguard platelet adhesion under high shear flow: Von Willebrand factor-glycoprotein Ib and integrin alphabeta-collagen interactions make complementary, collagen-Type-specific contributions to adhesion. J Thromb Haemost 2007;5:797-803
5. Weber C. Platelets and chemokines in atherosclerosis: Partners in crime. Circ Res 2005;96:612-16
6. Methia N, André P, Denis CV, et al. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001;98:1424-8
7. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009;113:3600-3
8. Fuster W, Bowie EJ, Lewis JC, et al. Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978;61:722-30
9. Sra'mek A, Bucciarelli P, Federici AB, et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: Results from a multicenter study in 47 patients. Circulation 2004;109:740-4
10. Conway DSG, Pearce LA, Chin BSP, et al. Plasma von Willebrand factor and soluble P-Selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors. Circulation 2002;106:1962-7
11. Bongers TN, de Maat MP, van Goor ML, et al. High von Willebrand factor levels increase the risk of first ischemic stroke. Influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006;37:2672-7
12. Lip GY, Land D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation stroke. Stroke 2006;37:2294-300
13. McCarty OJ, Conley RB, Shentu W, et al. Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging 2010;3:947-55
14. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood 1998;92:2791-801
15. Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood 1987;69:1531-4
16. Martin C, Morales LD, Cruz MA. Purified A2 domain of vonWillebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 2007;5:1363-70
17. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Iba and its complex with von Willebrand factor A1 domain. Science 2002;297:1176-9
18. Hsu TC, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood 2008;111:200-8
19. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990;6:217-46
20. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-9
21. De Ceunynck K, Rocha S, Feys HB, et al. Local elongation of endothelial cell-Anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem 2011;286:36361-7
22. Zanardelli S, Crawley JT, Chion CK, et al. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006;281:1555-63
23. de Groot R, Bardhan A, Ramroop N, et al. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood 2009;113:5609-16
24. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 2008;112:1713-19
25. Jakobi AJ, Mashaghi A, Tans SJ, Huizinga EG. Calcium modulates force sensing by the von Willebrand factor A2 domain. Nat Commun 2011;2:385
26. Xu AJ, Springer TA. Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding. Proc Natl Acad Sci USA 2012;109:3742-7
27. Bockmeyer CL, Claus RA, Budde U, et al. Inflammation-Associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008;93:137-40
28. Claus RA, Bockmeyer CL, Budde U, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009;101:239-47
29. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood 2010;115:706-12
30. Jin SY, Tohyama J, Bauer RC, et al. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler Thromb Vasc Biol 2012;32:1817-23
31. Jy W, Jimenez JJ, Mauro LM, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 2005;3:1301-8
32. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007;100:1673-85
33. Fredrickson BJ, Dong JF, McIntire LV, López JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998;92:3684-93
34. Wise RJ, Dorner AJ, Krane M, et al. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991;266:21948-55
35. Muntean W, Leschnik B. Factor VIII influences binding of factor IX and factor X to intact human platelets. Thromb Res 1989;55:537-48
36. Li X, Gabriel DA. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry 1997;36:10760-7
37. Freestone B, Chong AY, Nuttall S, Lip GY. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: Relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 2008;122:85-90
38. Blann AD, Kuzniatsova N, Lip GY. Vascular and platelet responses to aspirin in patients with coronary artery disease. Eur J Clin Invest 2013;43:91-9
39. Jessani SS, Lane DA, Shantsila E, et al. Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. Ann Med 2009;41:608-18
40. Freestone B, Gustafsson F, Chong AY, et al. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and N-Terminal pro B-Type natriuretic peptide levels in systolic heart failure. Chest 2008;133:1203-8
41. Karthikeyan VJ, Blann AD, Baghdadi S, et al. Endothelial dysfunction in hypertension in pregnancy: Associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. Clin Res Cardiol 2011;100:531-7
42. Foster W, Lip GY, Raza K, et al. An observational study of endothelial function in early arthritis. Eur J Clin Invest 2012;42:510-16
43. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998;98:294-9
44. Kaireviciute D, Lip GY, Balakrishnan B, et al. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J Thromb Haemost 2011;9:2345-52
45. Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011;57:2496-504
46. Ammash N, Konik EA, McBane RD, et al. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Thromb Vasc Biol 2011;31:2760-6
47. López JA, Dong JF. Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol 2004;41:15-23
48. Roldán V, Marín F, García-Herola A, Lip GY. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 2005;116:321-6
49. Navarrete AM, Casari C, Legendre P, et al. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood 2012;120:2723-32
50. Westein E, van der Meer AD, Kuijpers MJ, et al. Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci USA 2013;110:1357-62
51. Potapova IA, Cohen IS, Doronin SV. Von willebrand factor increases endothelial cell adhesiveness for human mesenchymal stem cells by activating p38 mitogen-Activated protein kinase. Stem Cell Res Ther 2010;1:35
52. Li S, Wang Z, Liao Y, et al. The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost 2010;8:341-50
53. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011;117:1400-7
54. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009;113:5049-57
55. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 2010;8:1689-701
56. Bae ON. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 2012;35:1693-9
57. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000;20:1347-53
58. Wadanoli M, Sako D, Shaw GD, et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 2007;98:397-405
59. Kageyama S, Yamamoto H, Nakazawa H, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol 2002;22:187-92
60. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol 2002;443:143-9
61. De Meyer SF, Staelens S, Badenhorst PN, et al. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor-collagen interaction in baboons. Thromb Haemost 2007;98:1343-9
62. Zhao YM, Jiang M, Ji SD, et al. Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochem Pharmacol 2013;85:945-53
63. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and shear stress. Blood 1996;88:1525-41
64. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011;118:757-65
65. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-vWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603-10
66. Siller-Matula JM, Merhi Y, Tanguay JF, et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol 2012;32:902-9
67. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678-86
68. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1787-93
69. Sobel M, Bird KE, Tyler-Cross R, et al. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation 1996;93:992-9
70. Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies. Blood 2006;107:3922-4
71. Barnes CS, Krafft B, Frech M, et al. Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin Thromb Hemost 2001;27:337-48
72. White TC, Berny MA, Robinson DK, et al. The leech product saratin is a potent inhibitor of platelet integrin alpha2beta1 and von Willebrand factor binding to collagen. FEBS J 2007;274:1481-91
73. Harsfalvi J, Stassen JM, Hoylaerts MF, et al. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood 1995;85:705-11
74. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010;10:267-77
75. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-89
76. Peterson NC. Advances in monoclonal antibody technology: Genetic engineering of mice, cells, and immunoglobulins. ILAR J 2005;46:314-19
77. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70:380-5
78. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999;20:344-53
79. Davi G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998;97:953-7
80. Folsom AR, Conlan MG, Davis CE, Wu KK. Relations between hemostasis variables and cardiovascular risk factors in middle-Aged adults: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol 1992;2:481-94
81. Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439-47
82. Lip GY, Blann AD, Jones AF, et al. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997;80:1566-71
83. Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-5
84. Wiman B, Andersson T, Hallqvist J, et al. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000;20:2019-23
85. Heper G, Murat SN, Durmaz T, Kalkan F. Prospective evaluation of von Willebrand factor release after multiple and single stenting. Angiology 2004;55:177-86
86. Kefer JM, Galanti LM, Desmet S, et al. Time course of release of inflammatory markers after coronary stenting: Comparison between bare metal stent and sirolimus-eluting stent. Coron Artery Dis 2005;16:505-9
87. Yamashita A, Furukoji E, Marutsuka K, et al. Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery. Arterioscler Thromb Vasc Biol 2004;24:2420-4
88. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002;297:1176-9